Literature DB >> 27436004

Psoriasis and psoriatic arthritis induced by nivolumab in a patient with advanced lung cancer.

Sarah Law-Ping-Man1, Antoine Martin2, Eric Briens3, Laurent Tisseau4, Gilles Safa5.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27436004     DOI： 10.1093/rheumatology/kew281

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN： 1462-0324            Impact factor:   7.580


× No keyword cloud information.
  20 in total

Review 1.  Management of the cutaneous adverse effects of antimelanoma therapy.

Authors:  Rose Congwei Liu; Germana Consuegra; Pablo Fernández-Peñas
Journal:  Melanoma Manag       Date:  2017-11-22

2.  Cutaneous Eruptions in Patients Receiving Immune Checkpoint Blockade: Clinicopathologic Analysis of the Nonlichenoid Histologic Pattern.

Authors:  Genevieve J Kaunitz; Manisha Loss; Hira Rizvi; Sowmya Ravi; Jonathan D Cuda; Karen B Bleich; Jessica Esandrio; Inbal Sander; Dung T Le; Luis A Diaz; Julie R Brahmer; Charles G Drake; Travis J Hollmann; Mario E Lacouture; Matthew D Hellmann; Evan J Lipson; Janis M Taube
Journal:  Am J Surg Pathol       Date:  2017-10       Impact factor: 6.394

3.  A Case of Anti-PD-L1-associated Remitting Seronegative Symmetric Synovitis With Pitting Edema.

Authors:  Jason M Redman; Logan P Rhea; Lisa Cordes; Helen Owens; Ravi A Madan; Marijo Bilusic; James L Gulley; Jung-Min Lee; William L Dahut; Fatima Karzai
Journal:  Clin Genitourin Cancer       Date:  2019-02-14       Impact factor: 2.872

Review 4.  Safety and Tolerability of Immune Checkpoint Inhibitors (PD-1 and PD-L1) in Cancer.

Authors:  Iosune Baraibar; Ignacio Melero; Mariano Ponz-Sarvise; Eduardo Castanon
Journal:  Drug Saf       Date:  2019-02       Impact factor: 5.606

5.  [Initially undetected de novo psoriasis triggered by nivolumab for metastatic base of the tongue carcinoma].

Authors:  S Troyanova-Slavkova; L Eickenscheidt; K Dumann; L Kowalzick
Journal:  Hautarzt       Date:  2018-08       Impact factor: 0.751

Review 6.  Dermatologic toxicities to immune checkpoint inhibitor therapy: A review of histopathologic features.

Authors:  Samantha R Ellis; Aren T Vierra; Jillian W Millsop; Mario E Lacouture; Maija Kiuru
Journal:  J Am Acad Dermatol       Date:  2020-04-29       Impact factor: 11.527

7.  Inflammatory Arthritis: A Newly Recognized Adverse Event of Immune Checkpoint Blockade.

Authors:  Jarushka Naidoo; Laura C Cappelli; Patrick M Forde; Kristen A Marrone; Evan J Lipson; Hans J Hammers; William H Sharfman; Dung T Le; Alan N Baer; Ami A Shah; Jemima Albayda; Rebecca L Manno; Uzma Haque; Anna Kristina Gutierrez; Clifton O Bingham; Julie R Brahmer
Journal:  Oncologist       Date:  2017-06-02

8.  A Case of De Novo Psoriasis Secondary to Nivolumab in a Patient With Metastatic Renal Cell Carcinoma.

Authors:  Sanjana Mullangi; Sreeja Ponnam; Manidhar Reddy Lekkala; Supriya Koya
Journal:  Cureus       Date:  2021-06-16

9.  Cancer immunotherapy-induced rheumatic diseases emerge as new clinical entities.

Authors:  Laura C Cappelli; Ami A Shah; Clifton O Bingham
Journal:  RMD Open       Date:  2016-09-28

10.  Immune checkpoint inhibitor PD-1 pathway is down-regulated in synovium at various stages of rheumatoid arthritis disease progression.

Authors:  Yanxia Guo; Alice M Walsh; Mary Canavan; Mihir D Wechalekar; Suzanne Cole; Xuefeng Yin; Brittney Scott; Mathew Loza; Carl Orr; Trudy McGarry; Michele Bombardieri; Frances Humby; Susanna M Proudman; Costantino Pitzalis; Malcolm D Smith; Joshua R Friedman; Ian Anderson; Loui Madakamutil; Douglas J Veale; Ursula Fearon; Sunil Nagpal
Journal:  PLoS One       Date:  2018-02-28       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.